XTRA:GXI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. More Details


Snowflake Analysis

Average dividend payer with moderate growth potential.


Similar Companies

Share Price & News

How has Gerresheimer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GXI is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GXI's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-3.4%

GXI

-5.2%

DE Life Sciences

1.3%

DE Market


1 Year Return

42.7%

GXI

61.4%

DE Life Sciences

1.1%

DE Market

Return vs Industry: GXI underperformed the German Life Sciences industry which returned 68.7% over the past year.

Return vs Market: GXI exceeded the German Market which returned 0.4% over the past year.


Shareholder returns

GXIIndustryMarket
7 Day-3.4%-5.2%1.3%
30 Day11.0%-5.7%4.5%
90 Day-2.6%-4.0%1.0%
1 Year44.8%42.7%62.2%61.4%4.3%1.1%
3 Year53.1%45.6%123.8%118.7%4.3%-4.8%
5 Year40.6%30.1%234.4%212.9%21.2%4.0%

Long-Term Price Volatility Vs. Market

How volatile is Gerresheimer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Gerresheimer undervalued compared to its fair value and its price relative to the market?

3.55x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: GXI (€96.8) is trading above our estimate of fair value (€92.44)

Significantly Below Fair Value: GXI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GXI is unprofitable, so we can't compare its PE Ratio to the XE Life Sciences industry average.

PE vs Market: GXI is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GXI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GXI is good value based on its PB Ratio (3.6x) compared to the XE Life Sciences industry average (4.6x).


Next Steps

Future Growth

How is Gerresheimer forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

19.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: GXI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GXI's is expected to become profitable in the next 3 years.

Revenue vs Market: GXI's revenue (5.6% per year) is forecast to grow slower than the German market (5.9% per year).

High Growth Revenue: GXI's revenue (5.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GXI's Return on Equity is forecast to be low in 3 years time (12.4%).


Next Steps

Past Performance

How has Gerresheimer performed over the past 5 years?

-5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GXI is currently unprofitable.

Growing Profit Margin: GXI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GXI is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare GXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GXI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.1%).


Return on Equity

High ROE: GXI has a negative Return on Equity (-2.7%), as it is currently unprofitable.


Next Steps

Financial Health

How is Gerresheimer's financial position?


Financial Position Analysis

Short Term Liabilities: GXI's short term assets (€558.2M) do not cover its short term liabilities (€909.7M).

Long Term Liabilities: GXI's short term assets (€558.2M) do not cover its long term liabilities (€802.4M).


Debt to Equity History and Analysis

Debt Level: GXI's debt to equity ratio (124.3%) is considered high.

Reducing Debt: GXI's debt to equity ratio has increased from 86.9% to 124.3% over the past 5 years.

Debt Coverage: GXI's debt is well covered by operating cash flow (21.7%).

Interest Coverage: GXI is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Gerresheimer current dividend yield, its reliability and sustainability?

1.24%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GXI's dividend (1.24%) is higher than the bottom 25% of dividend payers in the German market (1.12%).

High Dividend: GXI's dividend (1.24%) is low compared to the top 25% of dividend payers in the German market (3.64%).


Stability and Growth of Payments

Stable Dividend: GXI's dividends per share have been stable in the past 10 years.

Growing Dividend: GXI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: GXI is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: GXI's dividends in 3 years are forecast to be well covered by earnings (24.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Dietmar Siemssen (57 yo)

2yrs

Tenure

€2,103,000

Compensation

Mr. Dietmar Siemssen serves as CEO & Member of Management Board at Gerresheimer AG since November 01, 2018. He served as the Chairman of Management Board, Chief Executive Officer and Managing Director of S...


CEO Compensation Analysis

Compensation vs Market: Dietmar's total compensation ($USD2.50M) is about average for companies of similar size in the German market ($USD2.87M).

Compensation vs Earnings: Dietmar's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dietmar Siemssen
CEO & Member of Management Board2yrs€2.10mno data
Bernd Metzner
CFO & Member of the Management Board1.5yrs€991.00kno data
Lukas Burkhardt
Member of the Management Board2.83yrs€1.27mno data
Katja Schnitzler
Group Senior Director of EHS4.83yrs€106.00kno data
Jens-Philipp Briemle
Head of Investor Relations1yrno datano data
Jens Kürten
Group Senior Director of Communication & Marketing and Press Officer of Corporate Mediano datano datano data
Helmut Schweiger
MD & GM of Gerresheimer Horsovsky Tyn Plantno datano datano data

2.0yrs

Average Tenure

45.5yo

Average Age

Experienced Management: GXI's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Katja Schnitzler
Group Senior Director of EHS4.83yrs€106.00kno data
Axel Herberg
Independent Chairman of the Supervisory Board5.58yrs€257.00kno data
Peter Noé
Independent Member of the Supervisory Board8.83yrs€78.00kno data
Karin Louise Dorrepaal
Independent Member of the Supervisory Board8.58yrs€76.00kno data
Francesco Grioli
Deputy Chairman of the Supervisory Board8.92yrs€167.00kno data
Udo Vetter
Independent Member of the Supervisory Board13.5yrs€104.00kno data
Theodor Stuth
Independent Member of the Supervisory Board12.5yrs€126.00kno data
Markus Rocholz
Member of the Supervisory Board8.58yrs€132.00kno data
Heike Arndt
Member of the Supervisory Board3.58yrs€78.00kno data
Andrea Abt
Independent Member of the Supervisory Board5.58yrs€104.00kno data
Franz Hartinger
Member of the Supervisory Board3.58yrs€78.00kno data
Paul Schilling
Member of the Supervisory Board3.58yrs€78.00kno data

7.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: GXI's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Gerresheimer AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gerresheimer AG
  • Ticker: GXI
  • Exchange: XTRA
  • Founded: 1864
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.040b
  • Shares outstanding: 31.40m
  • Website: https://www.gerresheimer.com

Number of Employees


Location

  • Gerresheimer AG
  • Klaus-Bungert-Strasse 4
  • Düsseldorf
  • North Rhine-Westphalia
  • 40468
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GXIDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2007
0NTILSE (London Stock Exchange)YesCommon StockGBEURJun 2007
GRRM.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2007
GXIXTRA (XETRA Trading Platform)YesCommon StockDEEURJun 2007
GXIDBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURJun 2007
GXISWX (SIX Swiss Exchange)YesCommon StockCHCHFJun 2007
GXIWBAG (Wiener Boerse AG)YesCommon StockATEURJun 2007
GXI1DB (Deutsche Boerse AG)UNSPON ADR EA REPR ORDDEEURJan 2014

Biography

Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions;...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 22:15
End of Day Share Price2020/11/24 00:00
Earnings2020/08/31
Annual Earnings2019/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.